Please assess the completion status of the following clinical trial:

Trial Title: Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Male or female patients at least 18 years of age.~2. Patients currently on oral anticoagulation treatment with VKA of coumadin or warfarin type.~3. Patients being admitted to the hospital or currently hospitalized where:~   * an urgent surgery carrying significant bleeding risk (≥50 mL expected blood loss) is required as part of routine clinical care;~  * the use of oral or parenteral vitamin K alone to reverse anticoagulation is deemed too slow or inappropriate for reversal;~4. Patients with an international normalized ratio (INR) of 2.0 or above at the time of decision to reverse the anticoagulation status.~5. Patients who have given written informed consent and who are able and willing to comply with the procedures described in the study protocol.~Exclusion Criteria~1. Patients with a life expectancy of less than 48 hours per physician's judgment (e.g. patients with a Glasgow Coma Scale equal to 3 or a Head Abbreviated Injury Score of 6, patients requiring continuous inotropic or pressor support, and patients whose status is post cardiac arrest).~2. Patients for whom the planned surgery or procedure is commonly associated with a very low bleeding risk (e.g. catheter placement, gastroscopy).~3. Patients with a history of thromboembolic events (TEEs), myocardial infarction, unstable angina pectoris, critical aortic stenosis, cerebrovascular accident, transient ischemic attack, severe peripheral vascular disease, or disseminated intravascular coagulation within 3 months of enrollment.~4. Patients with a known congenital bleeding disorder.~5. Patients with a known antiphospholipid antibody syndrome.~6. Patients with present or past specific factor inhibitor activity.~7. Patients with thrombocytopenia of \<80,000/μL or history of heparin-induced thrombocytopenia.~8. Patients who have received heparin of any type or any non-VKA anticoagulant within 24 hours prior to enrollment into the study or with potential need to receive these medications before completion of hemostasis evaluation at the end of surgery.~9. Patients who have received prothrombin complex concentrates (PCCs), fresh frozen plasma or vitamin K within 72 hours prior to enrollment into the study.~10. Patients with a known history of hypersensitivity to plasma-derived products.~11. Patients with acute major bleeding or polytrauma.~12. Pregnant or nursing women.~13. Patients participating in another interventional clinical study currently or during the past 30 days prior to enrollment into this study.~14. Patients previously enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octaplex (Type: EXPERIMENTAL): Participants to receive1 Octaplex infusion intravenously
- Beriplex P/N (Kcentra) (Type: ACTIVE_COMPARATOR): Participants to receive1 Kcentra infusions intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).